The Science of Innovation
Our prodrugs are transformative— delivering better therapeutic indices and superior results for patients.
The Science of Innovation
Our prodrugs are transformative— delivering better therapeutic indices and superior results for patients.
Praesidia’s mission is to revolutionize Central Nervous System (CNS) targeted therapies, making them more effective and safer in addressing significant unmet needs.
The Problems We Face
CNS conditions cause more deaths than cardiovascular disease and cancer.
Conditions affecting the brain and nervous system are responsible for more illness and death worldwide than all other conditions.
Debilitating neurodegenerative disorders are becoming increasingly prevalent.
Alzheimer’s and Parkinson’s Disease rates are increasing substantially, while effective treatments remain out of reach.
Mental disorders and brain conditions are measuring at the highest levels ever.
Incidences of depression, eating disorders, schizophrenia, and epilepsy continue to rise at alarming rates.
Our Transformative Solution
Evolving CNS Therapies to Maximize their Potential
Central nervous system (CNS) disorders remain some of the most difficult to treat, often due to the challenges of safely delivering drugs across the blood-brain barrier. Many promising therapies are limited by off-target effects caused by poor brain selectivity and high systemic exposure.
We are working to meet these challenges with our novel prodrug platform designed to improve therapeutic indices – enabling brain-targeted drug activation while minimizing peripheral side effects.
The Praesidia approach has the potential to transform treatment across a wide range of CNS disorders.
Learn About our Approach
Praesidia’s Visionary Team
The Praesidia team brings together seasoned drug discovery experts with deep expertise in chemistry and biology, united by a shared commitment to advancing best-in-class therapeutics for CNS disorders.
Meet Our Team
Get in Touch
Meeting the best possible standard of care requires the cooperation of many. We welcome conversations with potential new partners, investors, and those who may contribute to our efforts.
Contact Us